Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RP3 |
| Trade Name | |
| Synonyms | RP 3|RP-3 |
| Drug Descriptions |
RP3 is an oncolytic virus engineered to express a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) targeting antibody, CD40 ligand, and tumor necrosis factor ligand superfamily member 9 (TNFSF9), which may result in activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C179624 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Bevacizumab + RP3 | Atezolizumab Bevacizumab RP3 | 0 | 2 |
| Carboplatin + Paclitaxel + RP3 | Carboplatin Paclitaxel RP3 | 0 | 1 |
| Cisplatin + RP3 | Cisplatin RP3 | 0 | 1 |
| Nivolumab + RP3 | Nivolumab RP3 | 0 | 1 |
| RP3 | RP3 | 0 | 1 |